Predictive Factors of Response and Real-World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

The study on 72 patients with alopecia areata assessed the effectiveness of baricitinib, revealing that 49% of patients achieved a significant response, which increased to 65% by Week 108. Key predictors of a positive response included a lower baseline Severity of Alopecia Tool (SALT) score, shorter disease duration, and longer treatment duration. Specifically, each point increase in the SALT score reduced response probability by 1.5%, and each additional year of disease reduced it by 2.7%, while each additional month of treatment increased response probability by 1.6%. Although factors like sex and immune-mediated comorbidities were not statistically significant, the study highlights the importance of personalized treatment approaches and suggests further research to optimize patient selection and understand the pathophysiology of alopecia areata.